Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Deviations in effective connectivity explain different hallucination subtypes in Parkinson's disease psychosis.

Nature. Mental health·2026

Same author

Machine learning to diagnose, classify and predict phenoconversion in isolated REM sleep behavior disorder.

Sleep medicine reviews·2026

Same author

Subcutaneous foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson's disease (aPD): societal cost impact analysis for the UK, France, Germany, Spain, and Canada.

Journal of medical economics·2026

Same author

Burden and disutility of sleep disturbance and early morning OFF symptoms in people with advancing Parkinson's disease: a vignette-based approach using the EQ-5D-5L.

Journal of patient-reported outcomes·2026

Same author

Exploring Preferences and Priorities in Advanced Parkinson's Disease: A Discrete Choice Experiment.

Neurology and therapy·2026

Same author

Patients with symmetric Parkinson's disease do poorly with subthalamic stimulation.

Journal of neurology, neurosurgery, and psychiatry·2026

Search research articles

Related Experiment Video

Updated: Feb 24, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Nonmotor Parkinson's and Future Directions.

Nataliya Titova¹, K Ray Chaudhuri²

¹Federal State Budgetary Educational Institution of Higher Education "N.I. Pirogov Russian National Research Medical University" of the Ministry of Healthcare of the Russian Federation, Moscow, Russia.

International Review of Neurobiology

|August 15, 2017

Summary

Nonmotor symptoms (NMS) significantly impact Parkinson's disease (PD) patients throughout their journey, yet remain poorly recognized and managed. Future research must prioritize NMS definition, management, and personalized therapies for improved quality of life.

Keywords:

Animal models Biomarkers Future directions Nonmotor subtypes Parkinson's disease Personalized medicine

More Related Videos

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease

Published on: June 17, 2013

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Related Experiment Videos

Last Updated: Feb 24, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease

Published on: June 17, 2013

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Area of Science:

Neurology
Neuroscience
Geriatrics

Background:

Nonmotor symptoms (NMS) are integral to Parkinson's disease (PD), affecting patients from prodromal stages through palliative care.
These symptoms significantly influence patient and caregiver quality of life.
Current recognition, management, and treatment of NMS in PD are inadequate.

Purpose of the Study:

To highlight the critical need for improved definition and management of NMS in Parkinson's disease.
To outline future research directions for understanding and treating NMS.
To emphasize the development of subtype-specific and personalized therapies for PD.

Main Methods:

Review of current understanding of NMS in PD.
Discussion of potential future research avenues, including animal models and biomarkers.
Exploration of personalized medicine approaches incorporating lifestyle and genetic factors.

Main Results:

NMS are a pervasive and impactful aspect of Parkinson's disease, affecting quality of life.
Existing management strategies for NMS are insufficient.
Future research should focus on mechanistic understanding, subtype identification, and personalized treatment.

Conclusions:

Enhanced focus on NMS definition and management is crucial for Parkinson's disease care.
Development of robust animal models, biomarkers, and subtype-specific therapies is needed.
Personalized medicine, considering diverse factors, offers a promising future for PD treatment.